NCT04027478 is a NA clinical trial of FMD in Chemotherapy Effect, sponsored by Sutter Health.

Who is sponsoring NCT04027478?

NCT04027478 is sponsored by Sutter Health.

What drugs are being tested in NCT04027478?

Interventions in NCT04027478: FMD.

What condition does NCT04027478 study?

NCT04027478 studies Chemotherapy Effect, Chemotherapeutic Toxicity, Fasting.

Is NCT04027478 still recruiting?

NCT04027478 is currently status unknown. Last updated 22 July 2019.

Last reviewed 2019-07-22 · How we verify

NCT04027478

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Can Fasting Decrease the Side Effects of Chemotherapy?

Status unknown NA Last updated 22 July 2019

What this trial tests

NA trial testing FMD in Chemotherapy Effect in 39 participants. Status unknown.

Timeline

1 September 2019

Primary endpoint
1 August 2020

1 February 2021

Quick facts

Lead sponsor	Sutter Health
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	supportive care
Enrollment	39
Start date	1 September 2019
Primary completion	1 August 2020
Estimated completion	1 February 2021
Sites	1 location across United States

Drugs / interventions tested

Conditions studied

Chemotherapy Effect — all drugs for Chemotherapy Effect →
Chemotherapeutic Toxicity — all drugs for Chemotherapeutic Toxicity →
Fasting — all drugs for Fasting →

Sponsor

Sutter Health — full company profile →

Who can join

18 and older, any sex, with Chemotherapy Effect or Chemotherapeutic Toxicity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective randomized crossover trial. Patients will be randomized to the FMD or regular diet during three rounds of chemotherapy. After the third round, patients will cross over to the opposite arm. The primary hypothesis is that there will be fewer cases of Grade 2-4 nausea when patients are in the FMD sequence. The primary objective is to assess differences in toxicities in patients undergoing chemotherapy with a combination of taxol/carboplatin when using a fasting mimicking diet when compared to normal diet before and after treatment.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Fasting-mimicking diet plus chemotherapy in breast cancer treatment.
Vernieri C, Ligorio F, Zattarin E, Rivoltini L, et al · · 2020 · cited 29× · PMID 32848145 · DOI 10.1038/s41467-020-18194-1
Short-term fasting and fasting mimicking diets combined with chemotherapy: a narrative review.
Kikomeko J, Schutte T, van Velzen MJM, Seefat R, et al · · 2023 · cited 10× · PMID 36970110 · DOI 10.1177/17588359231161418
Low Carbohydrate Diets in Cancer Therapeutics: Current Evidence.
Haskins C, Cohen J, Kotecha R, Kaiser A. · · 2021 · cited 5× · PMID 34901101 · DOI 10.3389/fnut.2021.662952
[The Role of Fasting-Mimicking Diet in Cancer Therapy: Mechanisms, Challenges, and Clinical Prospects].
Liu Y, Zhou L, Xue J. · · 2025 · PMID 40964112 · DOI 10.12182/20250560301

Verify or expand the search:

Other trials of FMD

Trials testing the same drug.

NCT06671613 — Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer · NA · recruiting
NCT05125913 — Long Term Cardio-Vascular Risk Assessment in CKD and Kidney Transplanted Patients Following SARS-COV-2 · unknown
NCT04409847 — COVID-19 Blood Pressure Endothelium Interaction Study (OBELIX) · completed
NCT04029571 — Effect and Safety of TCM-FMD in Phlegm-Dampness Type Overweight/Obesity Patients(EASTAR) · Phase 2 · completed
NCT03454282 — Impact of Dietary Intervention on Tumor Immunity: the DigesT Trial · NA · unknown

Other recruiting trials for Chemotherapy Effect

Currently open trials in the same condition.

NCT06525402 — Effect of Sodium Bicarbonate, Saline and Black Mulberry Syrup on Degree of Oral Mucositis in Children Receiving Chemothe · NA · recruiting
NCT06510010 — Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer · Phase 2 · recruiting
NCT06944587 — A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer · recruiting
NCT05864274 — Improve Cancer-related Cognitive Impairment · NA · recruiting
NCT06863623 — The Effect of Immersive Virtual Reality and Relaxing Videos on Lung Cancer Patients · NA · recruiting

Other Sutter Health trials

Trials by the same sponsor.

NCT06999369 — Heart Failure Food Intervention Trial: Impact of a Guideline-based Nutrition Digital Tool in Heart Failure Patient Clini · NA · enrolling by invitation
NCT04092647 — Ashwagandha for Cognitive Dysfunction · Phase 2 · unknown
NCT06689904 — The Effect of Eyedrop Size on Pupillary Dilation Using the Nanodropper Bottle Adapter · NA · completed
NCT05025150 — Point-of-Care Ultrasound for Pediatric Thoracic Trauma: A Multi-Institutional Trial · unknown
NCT05859087 — Family Planning Counseling for Women With Chronic Medical Conditions in an Inpatient Setting · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04027478 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sutter Health
Last refreshed: 22 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04027478.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing